Does tirzepatide cause constipation?

Yes. In SURMOUNT-1, constipation was reported by 16.8%, 17.1%, and 11.7% of participants assigned to 5 mg, 10 mg, and 15 mg, respectively, compared with 5.8% on placebo. The percentages describe whether participants reported constipation at least once; they do not predict its severity or duration for an individual.

How long does tirzepatide constipation last?

There is no established tirzepatide-specific duration. Gastrointestinal events tend to cluster during initiation and dose escalation, and many ease after the dose stabilizes. A broader GLP-1 consensus cited a 47-day median for constipation in people with obesity, but that is class-level context, not a tirzepatide countdown. Persistent or worsening symptoms merit a prescriber review.

What may help with constipation on tirzepatide?

Clinicians commonly review fluid intake, gradual fiber increases from food, regular movement, and whether reduced eating has left too little stool bulk. They also check other medicines and medical conditions that can contribute. If symptoms followed a dose increase, the prescriber may slow the escalation. Fluid and fiber advice should be individualized for kidney, heart, and digestive conditions.

Should the tirzepatide dose change because of constipation?

Dose changes belong with the prescriber. Mild constipation may improve while the current dose remains stable, while persistent symptoms may lead the clinician to delay an increase, hold the current level longer, or reconsider treatment. The decision depends on symptom severity, food and fluid intake, other medicines, medical history, and whether warning signs are present.

When is tirzepatide constipation serious?

It needs prompt assessment when there is a complete halt in passing stool or gas with vomiting or increasing abdominal swelling. Severe or persistent gastrointestinal symptoms also warrant a call. Severe, persistent abdominal pain that may radiate to the back, with or without vomiting, can signal pancreatitis and should not be treated as ordinary constipation.

Is semaglutide less likely to cause constipation?

Not reliably for an individual. Semaglutide also acts through the GLP-1 receptor and can cause constipation, so switching may not solve the symptom. A prescriber weighs the whole treatment profile—including response, other adverse effects, medical history, and the reason for treatment—before deciding whether another medication is a better clinical fit.

Tirzepatide Constipation: How Long It Lasts

Tirzepatide constipation can begin in the first weeks of treatment or return after a dose increase. It often eases once the dose has been stable for a while, but direct tirzepatide trials have not established one reliable duration for everyone. Hard stools, straining, and a clear drop from your normal bowel frequency all count. A pattern that keeps worsening, or comes with vomiting, swelling, or severe abdominal pain, needs clinical attention rather than more waiting.

How common is tirzepatide constipation?

The clearest dose-by-dose numbers come from SURMOUNT-1. This 72-week randomized trial enrolled 2,539 adults with obesity or overweight but without diabetes and included a 20-week dose-escalation period. In the New England Journal of Medicine report from 2022, constipation was reported more often with every tirzepatide dose than with placebo.

SURMOUNT-1 group	Participants reporting constipation
Placebo	5.8%
Tirzepatide 5 mg	16.8%
Tirzepatide 10 mg	17.1%
Tirzepatide 15 mg	11.7%

The 15 mg group’s lower rate does not mean a higher dose prevents constipation. These are group-level percentages, and the pattern did not rise neatly with dose. They describe how often participants reported the event at least once, not how severe it was or how long it lasted for a particular person.

When constipation starts and how long it lasts

Tirzepatide gastrointestinal effects cluster around treatment initiation and dose escalation. A 2025 analysis of SURMOUNT-1 through SURMOUNT-4 found that most gastrointestinal adverse events were non-serious and occurred during escalation. That makes a symptom’s relationship to a recent increase useful information for the prescriber. It does not guarantee that every case will fade on the same timetable.

Broader GLP-1 evidence adds context, with an important limit. A multidisciplinary expert consensus reported that constipation can begin within the first 16 weeks, especially the first 28 days, and cited a median duration of 47 days in people with obesity. That 47-day figure came from GLP-1 therapy data, not a tirzepatide-specific duration study. The honest answer is therefore an arc, not a countdown: early onset is common, improvement may follow stabilization, and persistent symptoms deserve review. The tirzepatide dosage schedule explains why escalation creates several adjustment points.

Why tirzepatide can slow bowel habits

Tirzepatide activates GIP and GLP-1 receptors. Its GLP-1 activity slows stomach emptying, which changes the pace at which a meal moves into the intestine. In a small human pharmacology study, gastric emptying slowed after a single tirzepatide dose. The effect diminished after repeated doses in participants without diabetes, while some delay remained during escalation in participants with type 2 diabetes.

That study measured the stomach, not colonic transit, so it does not explain constipation by itself. Food and fluid intake also tend to fall when appetite and meal size shrink. Less food means less stool bulk; less fluid can make stool harder. Those factors can overlap with lower activity, another constipating medicine, or a bowel condition that was present before treatment. The same medicine can also shift bowel habits in the other direction; tirzepatide diarrhea covers that separate symptom.

What a prescriber may discuss for relief

Management starts by identifying what changed and correcting the simplest contributors without creating a second problem. A clinician may discuss:

Fluid intake. The useful target depends on kidney function, heart conditions, climate, activity, and other sources of fluid. More is not automatically safer for everyone.
Fiber from food. Vegetables, fruit, beans, and whole grains can add stool bulk. A gradual change with adequate fluid is usually easier to tolerate than a sudden large increase.
Regular movement. Walking and ordinary daily activity can support bowel motility without turning symptom management into a workout plan.
Enough food overall. Very small meals may leave little material to form stool. A clinician or dietitian can look for a balance between appetite reduction and adequate nutrition.
The escalation pace. If symptoms appeared after an increase, the prescriber may hold the current level longer, delay the next increase, or reconsider the plan. The actual dose remains a prescriber decision.

It also matters whether iron, certain pain medicines, anticholinergic medicines, or another treatment could be contributing. Medication changes need an individualized review. For the wider adverse-event picture, tirzepatide side effects owns the overview.

Would semaglutide be different?

Not necessarily. Semaglutide acts at the GLP-1 receptor and can also cause constipation. Switching may produce a different experience for an individual, but a switch does not reliably provide tirzepatide constipation relief. A prescriber compares the entire clinical fit—including the reason for treatment, response, other adverse effects, medical history, and coverage—not one symptom in isolation.

What makes a clinical check-in useful

A useful message gives the date the bowel pattern changed, the date of the last dose increase, the last bowel movement, whether stool or gas can still pass, and whether pain, swelling, nausea, or vomiting is present. The provider will also want to know about fluid and food intake and any other medicines that changed.

Whether to delay an increase, hold a dose, or change medications is a decision for the patient and reviewing provider together. At Promise, a licensed provider reviews every request, and not everyone qualifies.

When constipation needs prompt care

As of August 2026, the current Zepbound prescribing information says gastrointestinal reactions can sometimes be severe and advises contacting a healthcare provider for severe or persistent symptoms. It also lists ileus—a failure of the bowel’s normal movement—among reactions reported after approval. Because those reports are voluntary, their frequency and a causal link cannot be established from the reports alone.

A complete halt in passing stool or gas together with vomiting or increasing abdominal swelling needs urgent assessment. Severe, persistent abdominal pain, particularly pain that may radiate to the back with or without vomiting, is also a label-based warning sign for pancreatitis rather than routine constipation. A mild change in frequency can be discussed at follow-up; these combinations should not wait for a routine visit.